Pharmacology	pharmacology	O	O
of	of	O	O
GYKI-41	gyki-41	O	O
099	099	O	O
(	(	O	O
chlorpropanol	chlorpropanol	O	O
,	,	O	O
Tobanum	tobanum	O	O
)	)	O	O
a	a	O	O
new	new	O	O
potent	potent	O	O
beta-adrenergic	beta-adrenergic	B_chemicals	O
antagonist	antagonist	I_chemicals	O
.	.	O	O

The	the	O	O
compound	compound	O	O
GYKI-41	gyki-41	O	O
099	099	O	O
,	,	O	O
as	as	O	O
a	a	O	O
beta-adrenergic	beta-adrenergic	B_chemicals	O
antagonist	antagonist	I_chemicals	O
,	,	O	O
is	is	O	O
3	3	O	O
-	-	O	O
8	8	O	O
times	times	O	O
more	more	O	O
potent	potent	O	O
than	than	O	O
propranolol	propranolol	S_chemicals	O
in	in	O	O
vitro	vitro	O	O
and	and	O	O
in	in	O	O
vivo	vivo	O	O
.	.	O	O

Its	its	O	O
antiarrhythmic	antiarrhythmic	O	O
effectiveness	effectiveness	O	O
surpasses	surpasses	O	O
that	that	O	O
of	of	O	O
propranolol	propranolol	S_chemicals	O
and	and	O	O
pindolol	pindolol	S_chemicals	O
inhibiting	inhibiting	O	O
the	the	O	O
ouabain	ouabain	S_chemicals	O
arrhythmia	arrhythmia	O	S_disease
in	in	O	O
dogs	dogs	O	O
and	and	O	O
cats	cats	O	O
.	.	O	O

GYKI-41	gyki-41	O	O
900	900	O	O
has	has	O	O
a	a	O	O
negligible	negligible	O	O
cardiodepressant	cardiodepressant	O	O
activity	activity	O	O
;	;	O	O
it	it	O	O
is	is	O	O
not	not	O	O
cardioselective	cardioselective	O	O
.	.	O	O

The	the	O	O
compound	compound	O	O
shows	shows	O	O
a	a	O	O
rapid	rapid	O	O
and	and	O	O
long	long	O	O
lasting	lasting	O	O
effect	effect	O	O
.	.	O	O

There	there	O	O
was	was	O	O
a	a	O	O
prolonged	prolonged	O	O
elimination	elimination	O	O
of	of	O	O
the	the	O	O
radioactivity	radioactivity	O	O
after	after	O	O
the	the	O	O
injection	injection	O	O
of	of	O	O
14C-41	14c-41	O	O
099	099	O	O
to	to	O	O
rats	rats	O	O
and	and	O	O
dogs	dogs	O	O
.	.	O	O

The	the	O	O
half	half	O	O
life	life	O	O
of	of	O	O
the	the	O	O
unlabeled	unlabeled	O	O
substance	substance	O	O
in	in	O	O
humans	humans	O	O
was	was	O	O
more	more	O	O
than	than	O	O
10	10	O	O
hours	hours	O	O
.	.	O	O

